---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Long-term morbidity"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Long-term morbidity. Topics: Loss of functional independence; Neuropsychiatric symptoms and functional capacity: systematic review; Falls and injury; Pneumonia, weight loss, dementia, and other comorbidities after diagnosis; 3 further topics. 7 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Loss of functional independence

> “Most individuals are forced to give up their employment and depend increasingly on others for help, although they are still able to maintain a considerable degree of personal independence.”
> “In late stages of HD, motor disability becomes severe, and the individual is often totally dependent, mute, and incontinent.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “They will eventually lose the ability to work, drive, and manage tasks at home, and may qualify for disability benefits.”
> “People with advanced HD need full-time care to help with their day-to-day activities, and they ultimately succumb to pneumonia, heart failure or other complications.”

Source: [Huntington's Disease Society of America (2020)](https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/)

<a id="topic-2.2.1.7-2"></a>

### Neuropsychiatric symptoms and functional capacity: systematic review

> “Significant associations with decreased functional capacity were found most commonly with depression (N=7, median r=0.48) and apathy (N=5, median r=0.47).”

Source: [Sellers et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31466515/)

<a id="topic-2.2.1.7-3"></a>

### Falls and injury

> “Twenty-seven patients (60%) reported two or more falls in the previous year and were classified as fallers. During prospective follow-up 40% reported at least one fall. A high proportion of falls (72.5%) caused minor injuries.”

Source: [Grimbergen et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18381643/)

> “Three months before death, anxiety (11% vs. 5%, 2.11, 0.7–5.6, p = 0.15), depression (28% vs. 6%, 4.28, 1.72–8.67, p < 0.001), falls (25% vs. 8%, 2.5, 1.18–4.73, p < 0.05), insomnia (25% vs. 4%, 8.82, 3.62–20.19, p < 0.001) and fractures/breaks/sprains (20% vs. 10%, 1.83, 0.85–3.35, p = 0.09) were more prevalent in HD cases.”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.7-4"></a>

### Pneumonia, weight loss, dementia, and other comorbidities after diagnosis

> “Incidence rates of the following were statistically higher in individuals with HD than controls: psychotic disorders, psychosis, insomnia, dementia, depression, pneumonia, weight loss and falls.”
> “The most commonly mentioned causes of death (any mention) were HD (78.3%), bronchopneumonia (unspecified) (15.9%), pneumonitis due to food and vomiting (10.4%), unspecified dementia (6.6%) and sepsis (6.6%) (Table S8).”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.7-5"></a>

### Aspiration pneumonia

> “It is most likely that dysphagia is the causative factor for this aspiration pneumonia.”

Source: [Heemskerk and Roos (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269785/)

<a id="topic-2.2.1.7-6"></a>

### Institutionalization: skilled nursing facility placement

> “Among 4,809 subjects enrolled, 3,070 had clinically definite HD. Of these, 228 (7.4%) resided in SNF. The SNF residents' average age was 52 years, average disease duration was 8.6 years, and they were predominantly women (63%).”
> “In the Cox model, bradykinesia (HR 1.965, 95% CI 1.083 to 3.564), impaired gait (HR 3.004, 95% CI 1.353 to 6.668), and impaired tandem walking (HR 2.546, 95% CI 1.460 to 4.439) were predictive of SNF placement.”

Source: [Wheelock et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12654967/)

<a id="topic-2.2.1.7-7"></a>

### Juvenile Huntington's disease: long-term motor morbidity and seizures

> “Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three [11%] in the LE subgroup vs eight [80%] in the HE subgroup; p<0·0001) prevailed over time in the HE subgroup.”

Source: [Fusilli et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30243861/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
